Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12485891 | 0.80 | BRD4 (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20503174 | 0.78 | POLB (0.32) | — | |
| SCHEMBL20503180 | 0.77 | FAAH (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2680434 | 0.75 | F2 (0.31) | — | |
| SCHEMBL5847509 | 0.75 | FAAH (0.39) | — | |
| SCHEMBL13284327 | 0.74 | CHRM2 (0.30) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3626814 | 0.73 | MGLL (0.41) | — | |
| SCHEMBL10794655 | 0.73 | MGLL (0.41) | — | |
| SCHEMBL11826435 | 0.70 | — | — | |
| SCHEMBL3468977 | 0.70 | POLB (0.31) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | MIRECA MEDICINES GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| EP-4399215-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | Mireca Medicines GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| CN-117999269-A | Improved process for producing cyclic guanosine monophosphate analogues | 米雷卡医药有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023031481-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2023-03-09 | — | — | WO | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| CN-113683548-B | Preparation method of 3, 4-dithiopyrrole material | 太原理工大学 | 2022-12-27 | — | — | CN | disclosed |
| CN-112500425-B | 3-thiopyrrole compound and synthesis method thereof | 太原理工大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-112358431-B | 3-thiopyrroline compound and synthetic method thereof | 太原理工大学 | 2022-02-15 | — | — | CN | disclosed |
| CN-113683548-A | Preparation method of 3, 4-dithiopyrrole material | 太原理工大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-112500425-A | 3-thiopyrrole compound and synthesis method thereof | 太原理工大学 | 2021-03-16 | — | — | CN | disclosed |
| CN-112358431-A | 3-thiopyrroline compound and synthetic method thereof | 太原理工大学 | 2021-02-12 | — | — | CN | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
| CN-108350018-A | The manufacturing method of oligonucleotides | 日产化学工业株式会社 | 2018-07-31 | — | — | CN | disclosed |
| EP-0127245-A2 | Carboxyamidine derivatives | NIPPON SODA CO., LTD. (JP) | 1984-12-05 | — | — | EP | disclosed |
| US-4068071-A | DISULFIDING, SOLVOLYSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | GMPS, CGAS, AMPD3 | LMNA 2593/4885CHRM2 4608/4885CHRM4 4325/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | LMNA 2077/4885CHRM2 4882/4885CHRM4 4736/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | LMNA 2077/4885CHRM2 4882/4885CHRM4 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.